| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1032742151 |
| P356 | DOI | 10.1186/1756-8935-8-9 |
| P932 | PMC publication ID | 4506402 |
| P698 | PubMed publication ID | 26191083 |
| P5875 | ResearchGate publication ID | 278729473 |
| P50 | author | Peggy Farnham | Q30503476 |
| P2093 | author name string | Seth Frietze | |
| Malaina Gaddis | |||
| Diana Gerrard | |||
| P2860 | cites work | Wnt/beta-catenin signaling in development and disease | Q27860784 |
| edgeR: a Bioconductor package for differential expression analysis of digital gene expression data | Q27860819 | ||
| The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor | Q28238069 | ||
| SREBP transcriptional activity is mediated through an interaction with the CREB-binding protein | Q28296757 | ||
| An integrated transcriptome and epigenome analysis identifies a novel candidate gene for pancreatic cancer | Q28392205 | ||
| Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes | Q28611357 | ||
| HTSeq--a Python framework to work with high-throughput sequencing data | Q29614489 | ||
| Epigenetic modifications and human disease | Q29619753 | ||
| A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected] | Q31106002 | ||
| ICG-001, a novel small molecule regulator of TCF/beta-catenin transcription | Q33247340 | ||
| Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials | Q33403391 | ||
| Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor | Q33599508 | ||
| The coactivators p300 and CBP have different functions during the differentiation of F9 cells | Q33727375 | ||
| KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. | Q33858490 | ||
| CBP and p300: HATs for different occasions | Q33980693 | ||
| Chromatin proteins and modifications as drug targets | Q34038652 | ||
| The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth | Q34041619 | ||
| Genome-wide assessment of differential roles for p300 and CBP in transcription regulation | Q34122513 | ||
| Wnt signaling in cancer | Q34262857 | ||
| Modification of enhancer chromatin: what, how, and why? | Q34331930 | ||
| Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal | Q34379557 | ||
| Molecular biology of pancreatic cancer | Q35085975 | ||
| p21Waf1/Cip1 as a therapeutic target in breast and other cancers | Q35620816 | ||
| Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma | Q35719620 | ||
| Wnt/beta-catenin signaling pathway as a novel cancer drug target | Q35971885 | ||
| Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis | Q36005381 | ||
| Regulation of cholesterol biosynthesis and cancer signaling | Q36418517 | ||
| Wnt signaling inside the nucleus | Q37051434 | ||
| Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: implications for histone acetyltransferase evolution and function | Q37290564 | ||
| Molecular pathways: sterols and receptor signaling in cancer | Q37383236 | ||
| Histone acetyl transferases as emerging drug targets. | Q37540911 | ||
| Targeting Wnt signaling: can we safely eradicate cancer stem cells? | Q37763415 | ||
| The Wnt signaling pathway in cellular proliferation and differentiation: A tale of two coactivators | Q37797633 | ||
| Wnt/β-catenin signaling in embryonic stem cell self-renewal and somatic cell reprogramming | Q37878387 | ||
| SREBP: a novel therapeutic target | Q38069003 | ||
| Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer | Q38945152 | ||
| Effect of Wnt inhibitors in pancreatic cancer. | Q38951399 | ||
| Canonical wnt signaling is required for pancreatic carcinogenesis | Q39140268 | ||
| Prognostic significance of WNT signaling in pancreatic ductal adenocarcinoma | Q39141618 | ||
| Cytoplasmic translocation of p21 mediates NUPR1-induced chemoresistance: NUPR1 and p21 in chemoresistance | Q39303333 | ||
| p8 expression controls pancreatic cancer cell migration, invasion, adhesion, and tumorigenesis | Q39587471 | ||
| Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. | Q39660739 | ||
| p8 is a new target of gemcitabine in pancreatic cancer cells | Q40333276 | ||
| Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression | Q40443907 | ||
| NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stress | Q46437952 | ||
| Targeting the epigenome for treatment of cancer. | Q53201323 | ||
| Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway. | Q55070717 | ||
| Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction | Q83188973 | ||
| Further case of Rubinstein-Taybi syndrome due to a deletion in EP300 | Q83624716 | ||
| P4510 | describes a project that uses | edgeR | Q113334690 |
| P304 | page(s) | 9 | |
| P577 | publication date | 2015-02-24 | |
| P1433 | published in | Epigenetics & Chromatin | Q15765513 |
| P1476 | title | Altering cancer transcriptomes using epigenomic inhibitors | |
| P478 | volume | 8 |
| Q64080156 | Digital expression explorer 2: a repository of uniformly processed RNA sequencing data |
| Q91792286 | Disruption of Broad Epigenetic Domains in PDAC Cells by HAT Inhibitors |
| Q36914561 | Effects on the transcriptome upon deletion of a distal element cannot be predicted by the size of the H3K27Ac peak in human cells |
| Q49427525 | Exon 3 mutations of CTNNB1 drive tumorigenesis: a review |
| Q92876708 | Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals |
| Q41718159 | Inhibition of Wnt/β-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer. |
| Q91776475 | Inhibition of acetylation of histones 3 and 4 attenuates aortic valve calcification |
| Q38363468 | Inhibition of different histone acetyltransferases (HATs) uncovers transcription-dependent and -independent acetylation-mediated mechanisms in memory formation |
| Q36757654 | Inhibition of p300 histone acetyltransferase activity in palate mesenchyme cells attenuates Wnt signaling via aberrant E-cadherin expression |
| Q47124134 | Integrative analysis to identify oncogenic gene expression changes associated with copy number variations of enhancer in ovarian cancer |
| Q90643583 | Lifespan-increasing drug nordihydroguaiaretic acid inhibits p300 and activates autophagy |
| Q48223411 | Pharmacological targeting of BET proteins attenuates radiation-induced lung fibrosis. |
| Q49237718 | Rimonabant Kills Colon Cancer Stem Cells without Inducing Toxicity in Normal Colon Organoids |
| Q47129410 | Stem Cells from Dental Pulp: What Epigenetics Can Do with Your Tooth |
| Q52715499 | Targeting Epigenetic Aberrations in Pancreatic Cancer, a New Path to Improve Patient Outcomes? |
| Q30383560 | The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases. |
| Q90476746 | Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature |
Search more.